Synairgen (LON:SNG) Stock Price Passes Below Two Hundred Day Moving Average of $24.38
Synairgen (LON:SNG) Stock Price Passes Below Two Hundred Day Moving Average of $24.38
Shares of Synairgen plc (LON:SNG – Get Rating) passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of GBX 24.38 ($0.28) and traded as low as GBX 17.20 ($0.20). Synairgen shares last traded at GBX 17.66 ($0.20), with a volume of 447,866 shares changing hands.
在周五的交易中，Synairgen plc(伦敦股票代码：SNG-GET评级)的股价跌破了200日移动均线。该股的200日移动均线为24.38英镑(合0.28美元)，交易价格低至17.20英镑(合0.20美元)。Synairgen的股票最后交易价格为17.66英镑(合0.2美元)，成交量为447,866股。
Synairgen Stock Down 1.9 %
Synairgen股价下跌1.9%
The firm's fifty day moving average price is GBX 19.57 and its two-hundred day moving average price is GBX 24.38. The stock has a market cap of £35.55 million and a price-to-earnings ratio of -0.73. The company has a debt-to-equity ratio of 0.09, a current ratio of 6.35 and a quick ratio of 6.35.
该公司的50日移动均线价格为19.57英镑，200日移动均线价格为24.38英镑。该股市值为3555万GB，市盈率为-0.73倍。该公司的债务权益比为0.09，流动比率为6.35，速动比率为6.35。
About Synairgen
关于Synairgen
(Get Rating)
(获取评级)
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease; and LOXL2 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) disease.
Synairgen plc发现和开发治疗呼吸系统疾病的药物。该公司开发的产品有：治疗新冠肺炎的乙型吸入型干扰素SG001；治疗感冒和流感引起的哮喘的乙型干扰素吸入剂；治疗或预防慢性阻塞性肺病的乙型干扰素第二阶段临床试验；以及治疗特发性肺纤维化的LXL2抑制剂。
Further Reading
进一步阅读
- MarketBeat: Week in Review 11/7 – 11/11
- Oil Is a Compelling Reason The Sell-Off In Stocks Isn't Over
- Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
- Six Flags is a Ride You Don't Want to Get Stuck On
- Hanesbrands May be Signaling a Bad Week for Retail Stocks
- MarketBeat：回顾中的一周11/7-11/11
- 油价是股市抛售尚未结束的一个令人信服的原因
- 中盘Neurocrine生物科学是井喷后的第三季度报告吗？
- 六面旗帜是一种你不想被困住的旅程
- Hanesbrand可能发出零售类股本周表现不佳的信号
Receive News & Ratings for Synairgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synairgen and related companies with MarketBeat.com's FREE daily email newsletter.
接受Synairgen Daily的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Synairgen和相关公司的最新新闻和分析师评级的每日简明摘要。